BioNTech SE
Develops cancer and infectious disease programs using immunotherapy and mRNA platforms; COMIRNATY is a named product with regulatory validation.
Corporate information
- Company entity
- BioNTech SE
- Headquarters / principal office
- Mainz, Rhineland-PalatinateSelf-reported location on the company LinkedIn page; regional scope may differ from the legal or global headquarters. ↗
- Founded
- 2008 ↗
- Ownership / capital status
- Publicly tradedPublicly traded ↗
- Official corporate reference
- https://www.biontech.com/ ↗
- LinkedIn company page
- LinkedIn ↗ ↗
- Latest financing / award identified
- 2019-10-10 · IPO (historical) · USD 150 million (excluding the overallotment option) ↗
Expected gross proceeds disclosed at pricing of the 2019 IPO; not the latest financing as of 2026.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Public evidence snapshot
Develops cancer and infectious disease programs using immunotherapy and mRNA platforms; COMIRNATY is a named product with regulatory validation.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.